seizure: Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure
Study Details
Study Description
Brief Summary
-
Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure.
-
Possible role to predict the prognosis of patients with epileptic seizure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Epilepsy is one of the most prevalent neurological disorders characterized by frequent somatic and psychiatric co-morbidities(1). Accurate diagnosis of epilepsy is challenging because clinicians rarely observe the actual clinical seizure outside of the hospital. Furthermore, psychogenic nonepileptic seizures (PNES) can mimic epileptic seizures (ES), leading to erroneous diagnosis and inappropriate treatments. A critical gap in the diagnostic assessment of seizures is a blood test that can distinguish ES from PNES (2). Both diagnoses were confirmed by the gold standard diagnostic method video/electroencephalogram (EEG) monitoring (3). Taking all in to account, the notion that neuro-inflammation is the key pathology behind focal epileptic seizure initiation and maintenance and the dynamic and adaptative process of neuro -inflammation is associated with blood-brain-barrier disruption and glial activation is no longer a surprise (4).
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates immune responses via apoptosis, with lower levels associated with severe infection, including sepsis (5). Monocyte chemoattractant protein-2 (MCP-2) has been well recognized to participate in immune regulation via binding to chemokine receptors and activation chemotaxis in lymphocytes T, natural killer (NK) cells, and monocytes therefore contributing to the pathogenesis of monocyte-dependent tissue injury (6). Hence, MCP-2 overexpression could result in an increased immune response. Further, since increased levels of MCP-2 have been observed in patients with Alzheimer's disease, this may further support the existence of the biodirections relationship between neurodegeneration and seizures/epilepsy (7).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Epileptic seizure Measuring inflammatory serum biomarkers in epileptic seizure patients and psychogenic non-epileptic seizure |
Other: Measuring inflammatory serum biomarkers
Measuring inflammatory serum biomarkers
|
Outcome Measures
Primary Outcome Measures
- 1- Evaluation of the role of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure [in first 24 hours of seizure]
Measurement of TRAIL and MCP-2 in differentiation between epileptic seizure and psychogenic non-epileptic seizure.
- 2- Possible role to predict the prognosis of patients with epileptic seizure. [in first 24 hours of seizure]
Differentiation between epileptic seizure and psychogenic non-epileptic seizure help in diagnosis and predict prognosis of seizure
Eligibility Criteria
Criteria
Inclusion Criteria:
- patients diagnosed as epileptic seizure are aged >12 years patients diagnosed as psychogenic non-epileptic seizure are aged >12 years Normal healthy control for comparison. Heathy control are aged >12 years with no history of lifetime seizures or suspected seizures or febrile seizure and no treatment with an antiepileptic drug (AED) prior to blood draw
Exclusion Criteria:
- Neurological criteria: Other CNS disorders including Parkinson's disease, amyotrophic lateral sclerosis ,cerebrovascular stroke, Psychiatric disorders {major depression disorder , generalized anxiety, mania and other psychiatric diseases).
Others: Tumors and cardiovascular
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Esraa Mostafa Ahmed Abdel Aal
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Serum biomarkers in seiz